Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bjoern-Oliver Gohlke

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Chemical Information and Modeling|August 15, 2018
Exploring Activity Profiles of PAINS and Their Structural Context in Target-Ligand ComplexesVishal B Siramshetty, Robert Preissner, Bjoern-Oliver Gohlke
Nucleic Acids Research|May 7, 2022
SuperPred 3.0: drug classification and target prediction-a machine learning approachKathleen Gallo, Andrean Goede, Robert Preissner, et al.
Nucleic Acids Research|November 22, 2015
CancerResource--updated database of cancer-relevant proteins, mutations and interacting drugsBjoern-Oliver Gohlke, Janette Nickel, Raik Otto, et al.
Nucleic Acids Research|November 16, 2023
Withdrawn 2.0-update on withdrawn drugs with pharmacovigilance dataKathleen Gallo, Andrean Goede, Oliver-Andreas Eckert, et al.
Nucleic Acids Research|November 11, 2015
WITHDRAWN--a resource for withdrawn and discontinued drugsVishal B Siramshetty, Janette Nickel, Christian Omieczynski, et al.
Nucleic Acids Research|November 7, 2017
mVOC 2.0: a database of microbial volatilesMarie C Lemfack, Bjoern-Oliver Gohlke, Serge M T Toguem, et al.
BMC Bioinformatics|September 26, 2015
2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug VatalanibBjoern-Oliver Gohlke, Tim Overkamp, Anja Richter, et al.
Nucleic Acids Research|June 1, 2014
SuperPred: update on drug classification and target predictionJanette Nickel, Bjoern-Oliver Gohlke, Jevgeni Erehman, et al.
Plos One|May 30, 2015
Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing HypersensitivityImir G Metushi, Amanda Wriston, Priyanka Banerjee, et al.
Science (New York, N.Y.)|December 2, 2017
The target landscape of clinical kinase drugsSusan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Chemical Information and Modeling|August 15, 2018
Exploring Activity Profiles of PAINS and Their Structural Context in Target-Ligand ComplexesVishal B Siramshetty, Robert Preissner, Bjoern-Oliver Gohlke
Nucleic Acids Research|May 7, 2022
SuperPred 3.0: drug classification and target prediction-a machine learning approachKathleen Gallo, Andrean Goede, Robert Preissner, et al.
Nucleic Acids Research|November 22, 2015
CancerResource--updated database of cancer-relevant proteins, mutations and interacting drugsBjoern-Oliver Gohlke, Janette Nickel, Raik Otto, et al.
Nucleic Acids Research|November 16, 2023
Withdrawn 2.0-update on withdrawn drugs with pharmacovigilance dataKathleen Gallo, Andrean Goede, Oliver-Andreas Eckert, et al.
Nucleic Acids Research|November 11, 2015
WITHDRAWN--a resource for withdrawn and discontinued drugsVishal B Siramshetty, Janette Nickel, Christian Omieczynski, et al.
Nucleic Acids Research|November 7, 2017
mVOC 2.0: a database of microbial volatilesMarie C Lemfack, Bjoern-Oliver Gohlke, Serge M T Toguem, et al.
BMC Bioinformatics|September 26, 2015
2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug VatalanibBjoern-Oliver Gohlke, Tim Overkamp, Anja Richter, et al.
Nucleic Acids Research|June 1, 2014
SuperPred: update on drug classification and target predictionJanette Nickel, Bjoern-Oliver Gohlke, Jevgeni Erehman, et al.
Plos One|May 30, 2015
Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing HypersensitivityImir G Metushi, Amanda Wriston, Priyanka Banerjee, et al.
Science (New York, N.Y.)|December 2, 2017
The target landscape of clinical kinase drugsSusan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm, et al.
Pageof 1